Saturday, 12 January 2013

Neuraltus Pharmaceuticals, Inc. Product Pipeline Review 2012: ResearchMoz include new market research report "Neuraltus Pharmaceuticals, Inc. Product Pipeline Review 2012" to its huge collection of research reports. Neuraltus Pharmaceuticals Inc. - Product Pipeline Review - 2012 provides data on the Neuraltus Pharmaceuticals, Inc.s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. 

This report is built using data and information sourced from Global Markets Directs proprietary databases, Neuraltus Pharmaceuticals, Inc.s corporate website, SEC filings, investor presentations and featured press releases, both from Neuraltus Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Directs team. 


- Neuraltus Pharmaceuticals, Inc. - Brief Neuraltus Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Neuraltus Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Neuraltus Pharmaceuticals, Inc. with complete description of the products developmental history, mechanism of action, therapeutic class, target and major milestones. 
- Recent updates of the Neuraltus Pharmaceuticals, Inc.s pipeline in the last quarter. 
- Key discontinued and dormant projects. 
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Neuraltus Pharmaceuticals, Inc.s strategic position with total access to detailed information on its product pipeline. 
- Assess the growth potential of Neuraltus Pharmaceuticals, Inc. in its therapy areas of focus. 
- Identify new drug targets and therapeutic classes in the Neuraltus Pharmaceuticals, Inc.s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. 
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. 
- Exploit collaboration and partnership opportunities with Neuraltus Pharmaceuticals, Inc.. 
- Avoid Intellectual Property Rights related issues. 
- Explore the dormant and discontinued projects of Neuraltus Pharmaceuticals, Inc. and identify potential opportunities in those areas.

For More Information, Please Visit@ Neuraltus Pharmaceuticals

Table Of Contents

List of Tables 3
List of Figures 3
Neuraltus Pharmaceuticals, Inc. Snapshot 4
Neuraltus Pharmaceuticals, Inc. Overview 4
Key Information 4
Key Facts 4
Neuraltus Pharmaceuticals, Inc. Research and Development Overview 5
Key Therapeutic Areas 5
Neuraltus Pharmaceuticals, Inc. Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products Monotherapy 8
Neuraltus Pharmaceuticals, Inc. Pipeline Products Glance 9
Neuraltus Pharmaceuticals, Inc. Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Neuraltus Pharmaceuticals, Inc. Early Stage Pipeline Products 10
Pre-Clinical Products/Combination Treatment Modalities 10
Neuraltus Pharmaceuticals, Inc. Drug Profiles 11
NP-001 11
Product Description 11
Mechanism of Action 11
R&D Progress 11
NP-002 13

Product Description 13
Mechanism of Action 13
R&D Progress 13
NP-003 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Neuraltus Pharmaceuticals, Inc. Pipeline Products by Route of Administration 15
Neuraltus Pharmaceuticals, Inc. Pipeline Products By Mechanism of Action 16
Neuraltus Pharmaceuticals, Inc. Recent Pipeline Updates 17
Neuraltus Pharmaceuticals, Inc. Locations And Subsidiaries 18
Head Office 18
Financial Deals Landscape 19
Neuraltus Pharmaceuticals, Inc., Deals Summary 19
Neuraltus Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details 20
Venture Financing 20
Neuraltus Pharma Raises Additional $1.5 Million In Venture Financing 20
Neuraltus Pharma Secures $17 Million In Series A Financing 21
Appendix 23
Methodology 23
Coverage 23
Secondary Research 23
Primary Research 23
Expert Panel Validation 23
Contact Us 24
Disclaimer 24

See All Biopharmaceutical Reports@

Contact: for further information. 

Find us on:

No comments:

Post a Comment